What You Should Know:
– Medable announced today that it is now partnering with Aural Analytics to test and develop remote digital data tools and harmonization methods designed to assess the wellbeing of patients undergoing cancer treatment.
– The addition of Aural Analytics’ speech biomarkers application improves outcomes data with important speech and language-based information about motor, cognitive, and respiratory function furthering the scope of digital measures which can be captured outside the cancer clinic.
Meable’s History with Cancer Moonshot Program
Medable received funding for the project in 2018 via the National Institute of Health’s Beau Biden Cancer Moonshot program. The Cancer Moonshot program was launched five years ago, infusing an additional $1.8 billion into cancer research via the 21st Century Cures Act passed by Congress. So far, 240 research projects across more than 70 initiatives have been supported by Moonshot funding, with more to come for the seven-year initiative.
Medable’s study, titled Digital Biomarkers for Care, is designed to test and develop remote data capture, analysis and integration tools to assess patients undergoing cancer treatment. Medable’s platform will use Aural Analytics to continuously capture data via patients’ iPhones, tracking physical and physiological parameters as they pertain to a patient’s perceived level of fatigue and physical capabilities.
“We’re excited to work with Aural Analytics to integrate speech collection as another method for remote data capture that fits easily into patients’ lives,” said Dr. Ingrid Oakley-Girvan, senior VP of research at Medable, and principal investigator for the Digital Biomarkers study. “Simple remote assessments reduce the burden on patients while removing geographic barriers to clinical trial participation. In many instances, longitudinal changes in remotely captured data will become essential for monitoring therapy-related declines and documenting early improvements. This will enable clinical teams to better serve patients and reduce trial timelines.”
